Gain Therapeutics(GANX)
BETHESDA, MD
BiotechnologyFocus: Site-directed Enzyme Enhancement Therapy
Gain Therapeutics is a life sciences company focused on Site-directed Enzyme Enhancement Therapy.
NeurologyMetabolic Diseases
Funding Stage
PUBLIC
Total Funding
$300M
Open Jobs
0
Pipeline & Clinical Trials
High animal protein diet group
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT02402985Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics
N/AEnvita Stories Methodology in Long-term care Centres for old adults
Long-term Care Centres for Old Adults UsersClinical Trials (1)
NCT06569628Validation of a Life Stories Methodologies in Long-Term Care Centres
N/AGT-02287
Parkinson DiseaseClinical Trials (1)
NCT06732180Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
Phase 1Low Dose GT-02287
Parkinson DiseaseClinical Trials (1)
NCT07280299Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2023
Portfolio: 4 clinical trials
SEC Filings: 2 available
Financials (FY2024)
Revenue
$55K61%
R&D Spend
$12M(20878%)38%
Net Income
-$22MCash
$12M